LUND, Sweden, July 29, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced three leadership appointments. Brian Gorman joins Hansa as Chief Legal Officer and Corporate Secretary, effective August 4; Sandra Frithiof has been appointed Chief Human Resources Officer (CHRO), effective August 4; and Kerstin Falck Lagercrantz will join the company September 1, as Vice President Corporate Affairs. These three experienced executives will support Hansa's growth and further enhance the company's expertise across legal, human resources and corporate affairs.

LUND, Sweden, July 29, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced three leadership appointments. Brian Gorman joins Hansa as Chief Legal Officer and Corporate Secretary, effective August 4; Sandra Frithiof has been appointed Chief Human Resources Officer (CHRO), effective August 4; and Kerstin Falck Lagercrantz will join the company September 1, as Vice President Corporate Affairs. These three experienced executives will support Hansa's growth and further enhance the company's expertise across legal, human resources and corporate affairs.

LUND, Sweden, July 17, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced its interim report for January-June 2025.

Renée Aguiar-Lucander, CEO, Hansa Biopharma said, "In Q2 2025, the Company successfully secured additional financing and restructured its existing debt agreement with NovaQuest, ensuring the ability to report out data on two key Phase 3 programs in kidney transplantation and anti-GBM. With a cash runway now extending into Q2 2026, we can focus on near term catalysts, strategic pipeline decisions and driving the continued commercialization of IDEFIRIX in Europe."

LUND, Sweden, July 17, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced its interim report for January-June 2025.

Renée Aguiar-Lucander, CEO, Hansa Biopharma said, "In Q2 2025, the Company successfully secured additional financing and restructured its existing debt agreement with NovaQuest, ensuring the ability to report out data on two key Phase 3 programs in kidney transplantation and anti-GBM. With a cash runway now extending into Q2 2026, we can focus on near term catalysts, strategic pipeline decisions and driving the continued commercialization of IDEFIRIX in Europe."

LUND, Sweden, July 8, 2025 /PRNewswire/ --  Hansa Biopharma AB, "Hansa" (NASDAQ Stockholm: HNSA) today announced that Dr. Richard Philipson has been appointed Chief Medical Officer (CMO) effective 14 July. Dr Philipson will report to CEO Renée Aguiar-Lucander and be a member of the Executive Committee.

Dr Philipson has over 25 years of industry experience and a successful track record in drug development, providing clinical leadership resulting in four product approvals, including in rare disease and gene therapy, and comes with expertise and success in building high-functioning teams, building pipelines and executing clinical development programs across all phases of development.  He also brings in-depth knowledge of regulatory strategy in drug development. Dr Philipson most recently was CMO of Calliditas Therapeutics and previously spent 16 years at GlaxoSmithKline (GSK), including four years as Therapeutic Area Head in the Rare Diseases Unit. He also has experience from Takeda, and a 4-year period as CMO at Trizell. 

LUND, Sweden, July 8, 2025 /PRNewswire/ --  Hansa Biopharma AB, "Hansa" (NASDAQ Stockholm: HNSA) today announced that Dr. Richard Philipson has been appointed Chief Medical Officer (CMO) effective 14 July. Dr Philipson will report to CEO Renée Aguiar-Lucander and be a member of the Executive Committee.

Dr Philipson has over 25 years of industry experience and a successful track record in drug development, providing clinical leadership resulting in four product approvals, including in rare disease and gene therapy, and comes with expertise and success in building high-functioning teams, building pipelines and executing clinical development programs across all phases of development.  He also brings in-depth knowledge of regulatory strategy in drug development. Dr Philipson most recently was CMO of Calliditas Therapeutics and previously spent 16 years at GlaxoSmithKline (GSK), including four years as Therapeutic Area Head in the Rare Diseases Unit. He also has experience from Takeda, and a 4-year period as CMO at Trizell. 

LUND, Sweden, June 30, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), announced today the presentation of its five year extended pooled analysis including data from the 17-HMedIdeS-14 study, an international long-term follow-up study of patients who have received a kidney transplant following desensitization with imlifidase, at the 2025 International Transplant Congress of the European Society for Organ Transplantation (ESOT), taking place in London, June 29 – July 2.

LUND, Sweden, June 30, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), announced today the presentation of its five year extended pooled analysis including data from the 17-HMedIdeS-14 study, an international long-term follow-up study of patients who have received a kidney transplant following desensitization with imlifidase, at the 2025 International Transplant Congress of the European Society for Organ Transplantation (ESOT), taking place in London, June 29 – July 2.

LUND, Sweden, June 11, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (NASDAQ Stockholm: HNSA), today announced that Hansa's CEO Renée Aguiar-Lucander will speak at the BIO International Convention at the Boston Convention & Exhibition Center, Boston, MA, June 16-19.

Aguiar-Lucander will participate in a panel entitled "European Biotech: Unlocking Investment Opportunities" and will be available for meetings at the conference. If you are interested in meeting with Aguiar-Lucander, please contact Hansa Biopharma at ir@hansabiopharma.com. To learn more about Hansa Biopharma see the latest Corporate Presentation here. The latest investor presentation can be viewed here.

LUND, Sweden, June 11, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (NASDAQ Stockholm: HNSA), today announced that Hansa's CEO Renée Aguiar-Lucander will speak at the BIO International Convention at the Boston Convention & Exhibition Center, Boston, MA, June 16-19.

Aguiar-Lucander will participate in a panel entitled "European Biotech: Unlocking Investment Opportunities" and will be available for meetings at the conference. If you are interested in meeting with Aguiar-Lucander, please contact Hansa Biopharma at ir@hansabiopharma.com. To learn more about Hansa Biopharma see the latest Corporate Presentation here. The latest investor presentation can be viewed here.